AB

Apurva Bhupendra Shah

Active Director Director DIN 00378260
DIN 00378260 First appointment Jun 2012 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 8 active board seats
Past companies 7 historical roles
Total affiliations 15 Since Jun 2012
Shareholding value β€’β€’β€’β€’ Premium profile
Directorship timeline
First appointment 19 Jun 2012
Active appointments 9
Total timeline records 15

Apurva Bhupendra Shah (DIN 00378260) has 15 recorded board appointments in Indian companies, the first from June 2012, of which 9 are current. The chart and the list below show each company, the role held and the years of the appointment, as filed with the Ministry of Corporate Affairs.

Appointment history

Since 2012
Veeda Clinical Research Limited Director · 2026 – present
Current
Zylo House Of Brands Private Limited Director · 2025 – present
Current
Zetts Cosmetics Private Limited Director · 2024 – present
Current
Gsg Pharmaceuticals Private Limited Director · 2022 – present
Current
Flint Management Consultants Llp Partner · 2021 – present
Current
Enzu.Life Private Limited Director · 2020 – present
Current
Saascorp Llp Designated Partner · 2020 – present
Current
Jiwa Foods Private Limited Director · 2016 – present
Current
Shilpveda Infracon Llp Designated Partner · 2012 – present
Current
Tehoco Ventures Private Limited Director · 2024 – 2024
Previous
Strawberry Polymers Private Limited Additional Director · 2015 – 2016
Previous
Alfa Corpuscles Private Limited Director · 2014 – 2018
Previous
Previous
Synersoft Technologies Private Limited Additional Director · 2013 – 2013
Previous
Point Hospitals Private Limited Director · 2012 – 2026
Previous

Interactive timeline

Hover bars for tenure details
Loading chart...
Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available